A completely new activity of FOXM1, mediated through steroid/cholesterol biosynthetic process and protein secretion in cancer cells was also detected. Collectively, STL001 offers intriguing translational opportunities as combination therapies targeting FOXM1 activity in a variety of human cancers driven by FOXM1.

P1, N=50, Not yet recruiting, Medical University of South Carolina | Initiation date: Feb 2024 --> Jan 2025

The ideal environment for tyrosine kinase inhibitor therapy is produced by a favorable oxidative status. We discuss the latest studies that aim to manipulate the redox system to alter the apoptosis of cancerous cells.

P=N/A, N=100, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

This validated phenotypic characterization of a large number of patients with CS will allow future researchers to make a positive diagnosis, and to differentiate CS from CFCS and NS.

Low concentrations of adapalene can induce differentiation of SH-SY5Y cells into mature functional neurons, while high concentrations of adapalene can induce apoptosis in SH-SY5Y cells.

Among systemic non-biologics, acitretin was the most frequently prescribed, followed by ciclosporin and methotrexate. The onset age for ACH among Asian patients is earlier (late 30s) than that for Caucasian patients (late 40s). Interleukin-17 inhibitors may be more effective than tumour necrosis factor inhibitors in managing ACH.

P3, N=209, Active, not recruiting, Timber Pharmaceuticals Inc. | N=142 --> 209 | Recruiting --> Active, not recruiting

P2/3, N=270, Recruiting, Laurent Pharmaceuticals Inc. | N=204 --> 270

P1, N=18, Recruiting, Dwight Owen | Trial primary completion date: Dec 2023 --> Dec 2024

P2/3, N=125, Active, not recruiting, Laurent Pharmaceuticals Inc. | Trial completion date: Dec 2023 --> May 2024

P3, N=142, Recruiting, Timber Pharmaceuticals Inc. | Trial completion date: May 2024 --> Nov 2024 | Trial primary completion date: Mar 2024 --> Sep 2024

P4, N=25, Completed, Beth Israel Deaconess Medical Center | N=37 --> 25

M3-like patients exhibited distinct genomic features, low immune activity and better clinical survival. The initiative identification of patients similar to M3 subtype may help to identify more patients that would benefit from ATO/ATRA treatment and deepen our understanding of the molecular mechanism of AML pathogenesis.

P1, N=50, Not yet recruiting, Medical University of South Carolina

P3, N=379, Active, not recruiting, Children's Oncology Group | Trial completion date: Jan 2024 --> Jan 2025

P3, N=379, Active, not recruiting, Children's Oncology Group | Trial completion date: Jul 2028 --> Jan 2024

The gene transcription profile and metabolites of FLT3-ITD mutant cells changes significantly after treatment, which might be related to the anti-FLT3-ITD AML effect. The screened DEGs, differential metabolites pathway are helpful in studying the mechanism of anti-leukemia effects and drug targets.

Amongst the library of compounds, Adapalene exhibited the least binding energy of (-10.2 kCal/mol) in comparison to that of the chosen reference compound, Nilutamide (-8.6 kCal/mol). However, the overall effect of Adapalene was significantly lower in the case of MDA-MB-231 cell lines, which could be attributed to its inherent nature of the absence of hormone receptors. Conclusively, Adapalene possesses greater therapeutic efficacy in comparison to the control drug, thereby hinting towards the potential use of Adapalene in the treatment of AR-positive breast cancer.

Although tandem HDC/ASCT showed promising outcomes, the I-MIBG combination did not improve survival rates.

P1, N=46, Recruiting, SciTech Development, LLC

P2/3, N=204, Recruiting, Laurent Pharmaceuticals Inc. | Not yet recruiting --> Recruiting

P4, N=36, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Nov 2023 | Trial primary completion date: Jul 2026 --> Nov 2023

Therefore, in this study, we aim to summarize the current understanding of BCSCs, their biomarkers, and the associated signaling pathways. Retinoids, such as Adapalene, a third-generation retinoid, have shown promising anti-cancer potential and may serve as therapeutic agents to target BCSCs.

P1, N=46, Recruiting, SciTech Development, LLC | Not yet recruiting --> Recruiting | Phase classification: P1a/1b --> P1

P2/3, N=125, Active, not recruiting, Laurent Pharmaceuticals Inc. | Recruiting --> Active, not recruiting | N=508 --> 125

P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Oct 2025 --> Sep 2024

Methods Data used in this study included RNA (n=143) and whole exome (n=126) sequencing data from available FFPE tumor samples at the time of a relapse (any line of treatment, r1-r10 relapse timepoints included in analysis, one per patient), consented to the Molecular Epidemiology Resource (n=61), banked in the Mayo Lymphoma Biobank (n=50), or consented to the CC-122-ST-001 clinical trial (n=32, NCT01421524). In summary, we show for the first time that rrDLBCL patients can be classified into four gene expression clusters that are associated with distinct pathway, TME, and genetic programs. These clusters should now be tested to learn if they can help select patients for newer therapies for rrDLBCL such as CAR-T and bispecific antibodies.

P2, N=112, Recruiting, Mario Negri Institute for Pharmacological Research | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Aug 2023 --> Aug 2024

P1/2, N=26, Active, not recruiting, University of Colorado, Denver | Trial completion date: Aug 2023 --> Aug 2024

P2, N=151, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> Dec 2025

Both options of treatment (ATRA-ATO and ATRA-chemotherapy) were discussed with patients with low- and intermediate-risk APL, pros and cons explained in details, and treatment regimen selected after getting informed written consent. Fifteen patients liked to be treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), while rest of the 15 patients preferred treatment with ATRA and chemotherapy. Combination of ATRA and ATO is equally effective, less toxic, and more feasible in comparison to ATRA and chemotherapy for patients with low- and intermediate-risk APL and is a viable option for this subset of patients, especially in countries with limited resources.

In conclusion, none of the antioxidants tested so far (α-tocopherol, β-carotene, JP, Isotretinoin, interferon α-2a, vitamin E, retinyl palmitate, N-acetylcysteine) was effective in preventing second primary tumors in HNSCC patients, and they could only be used in reducing the side effects of radiotherapy. Further research is needed to better understand the interplay between antioxidants and cancer outcomes in this context.

Therefore, this information is essential to clinicians for deciding on the appropriate use of isotretinoin. In this article, we aim to review the most updated evidence-based data about the use of oral isotretinoin in dermatology.

Finally, adapalene impeded tumor growth in a xenograft tumor zebrafish model. In summary, the discovery of the vitamin A derivative adapalene as a c-MYC inhibitor reveals its potential as an avant-garde treatment for MM.

Even in the case of relapses, most patients obtain a new remission as a result of therapy with ATO and ATRA, but an effective consolidation treatment is necessary to maintain it. However, there is a variety of controversial aspects related to the role of HSCT in APL, ranging from the fact that outcome data are obtained almost exclusively from retrospective studies and historical analyses to questions related to the type of transplantation, the impact of minimal residual disease, conditioning regimens, or the role of other therapeutic options. All these questions justify the need for controlled prospective studies in the following years.

Tailored treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the outcome of acute promyelocytic leukemia (APL) from a uniformly fatal disease to one of the most curable malignant diseases in humans. Due to its high efficacy, ATO/ATRA is the standard first-line therapy in younger adult, non-high-risk APL patients...Besides the treatment of newly diagnosed patients, managing toxicities and complications remains challenging. This review discusses the approach to the treatment of APL in elderly and pediatric patients.

Since the introduction of all-trans retinoic acid (ATRA), acute promyelocytic leukemia (APL) has become a highly curable malignancy, especially in combination with arsenic trioxide (ATO)...Furthermore, recent super-enhancer (SE) analysis has identified a novel AML subgroup characterized by high expression of RARα through strong SE levels in the gene locus and increased sensitivity to tamibarotene. Combined with a hypomethylating agent, synthetic retinoids have shown synergistic anti-leukemic effects in non-APL AML preclinical models and are now being studied in phase II and III clinical trials.

In human ACCs, myoepithelial-like cells act as progenitors of ductal-like cells, and myoepithelial-to-ductal differentiation is promoted by RAR/RXR signaling. Suppression of RAR/RXR signaling is lethal to ductal-like cells and represents a new therapeutic approach against human ACCs.

Treatment with oral acitretin 20 mg/d was started with marked response...Inheritance is autosomal dominant with incomplete penetrance. De novo mutations are possible which may explain the absence of a family history of KA in our patient